Header Logo

Connection

ZHONGXING LIAO to Follow-Up Studies

Back to Details
This is a "connection" page, showing publications ZHONGXING LIAO has written about Follow-Up Studies.
ZHONGXING LIAO
Connection Strength
0.376
Follow-Up Studies
  1. Propensity score-based comparison of long-term outcomes with 3-dimensional conformal radiotherapy vs intensity-modulated radiotherapy for esophageal cancer. Int J Radiat Oncol Biol Phys. 2012 Dec 01; 84(5):1078-85.
    View in: PubMed
    Score: 0.036
  2. Long-term clinical outcome of intensity-modulated radiotherapy for inoperable non-small cell lung cancer: the MD Anderson experience. Int J Radiat Oncol Biol Phys. 2012 May 01; 83(1):332-9.
    View in: PubMed
    Score: 0.034
  3. Genotypes and haplotypes of the VEGF gene and survival in locally advanced non-small cell lung cancer patients treated with chemoradiotherapy. BMC Cancer. 2010 Aug 16; 10:431.
    View in: PubMed
    Score: 0.031
  4. Long-Term Clinical, Radiological, and Mortality Outcomes Following Pneumonitis in Nonsmall Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors: A Retrospective Analysis. Clin Lung Cancer. 2024 Nov; 25(7):624-633.e2.
    View in: PubMed
    Score: 0.021
  5. Twice daily irradiation increases locoregional control in patients with medically inoperable or surgically unresectable stage II-IIIB non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2002 Jul 01; 53(3):558-65.
    View in: PubMed
    Score: 0.018
  6. Mantle irradiation alone for pathologic stage I and II Hodgkin's disease: long-term follow-up and patterns of failure. Int J Radiat Oncol Biol Phys. 2001 Jul 15; 50(4):971-7.
    View in: PubMed
    Score: 0.017
  7. Locoregional irradiation for inflammatory breast cancer: effectiveness of dose escalation in decreasing recurrence. Int J Radiat Oncol Biol Phys. 2000 Jul 15; 47(5):1191-200.
    View in: PubMed
    Score: 0.016
  8. Postoperative Radiotherapy for Locally Advanced NSCLC: Implications for Shifting to Conformal, High-Risk Fields. Clin Lung Cancer. 2021 05; 22(3):225-233.e7.
    View in: PubMed
    Score: 0.016
  9. Giant Circulating Cancer-Associated Macrophage-Like Cells Are Associated With Disease Recurrence and Survival in Non-Small-Cell Lung Cancer Treated With Chemoradiation and Atezolizumab. Clin Lung Cancer. 2021 05; 22(3):e451-e465.
    View in: PubMed
    Score: 0.016
  10. Locoregional Control, Overall Survival, and Disease-Free Survival in Stage IIIA (N2) Non-Small-Cell Lung Cancer: Analysis of Resected and Unresected Patients. Clin Lung Cancer. 2020 07; 21(4):e294-e301.
    View in: PubMed
    Score: 0.015
  11. Immune and Circulating Tumor DNA Profiling After Radiation Treatment for Oligometastatic Non-Small Cell Lung Cancer: Translational Correlatives from a Mature Randomized Phase II Trial. Int J Radiat Oncol Biol Phys. 2020 02 01; 106(2):349-357.
    View in: PubMed
    Score: 0.015
  12. Recurrence Risk Stratification After Preoperative Chemoradiation of Esophageal Adenocarcinoma. Ann Surg. 2018 08; 268(2):289-295.
    View in: PubMed
    Score: 0.014
  13. Subdiaphragmatic stage I & II Hodgkin's disease: long-term follow-up and prognostic factors. Int J Radiat Oncol Biol Phys. 1998 Jul 15; 41(5):1047-56.
    View in: PubMed
    Score: 0.014
  14. Recursive Partitioning Analysis Identifies Pretreatment Risk Groups for the Utility of Induction Chemotherapy Before Definitive Chemoradiation Therapy in Esophageal Cancer. Int J Radiat Oncol Biol Phys. 2017 10 01; 99(2):407-416.
    View in: PubMed
    Score: 0.013
  15. 7-year follow-up after stereotactic ablative radiotherapy for patients with stage I non-small cell lung cancer: Results of a phase 2 clinical trial. Cancer. 2017 Aug 15; 123(16):3031-3039.
    View in: PubMed
    Score: 0.012
  16. Factors Predictive of Improved Outcomes With Multimodality Local Therapy After Palliative Chemotherapy for Stage IV Esophageal Cancer. Am J Clin Oncol. 2016 06; 39(3):228-35.
    View in: PubMed
    Score: 0.012
  17. Comparison of locoregional versus extended locoregional radiation volumes for patients with nonmetastatic gastro-esophageal junction carcinomas. J Thorac Oncol. 2015 Mar; 10(3):518-26.
    View in: PubMed
    Score: 0.011
  18. Prognostic value and reproducibility of pretreatment CT texture features in stage III non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2014 Nov 15; 90(4):834-42.
    View in: PubMed
    Score: 0.010
  19. Re-evaluating the optimal radiation dose for definitive chemoradiotherapy for esophageal squamous cell carcinoma. J Thorac Oncol. 2014 Sep; 9(9):1398-405.
    View in: PubMed
    Score: 0.010
  20. Factors associated with local-regional failure after definitive chemoradiation for locally advanced esophageal cancer. Ann Surg Oncol. 2014 Jan; 21(1):306-14.
    View in: PubMed
    Score: 0.010
  21. A phase II randomized trial of induction chemotherapy versus no induction chemotherapy followed by preoperative chemoradiation in patients with esophageal cancer. Ann Oncol. 2013 Nov; 24(11):2844-9.
    View in: PubMed
    Score: 0.010
  22. Phase 1 study of dose escalation in hypofractionated proton beam therapy for non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2013 Jul 15; 86(4):665-70.
    View in: PubMed
    Score: 0.009
  23. Prescribing radiation dose to lung cancer patients based on personalized toxicity estimates. J Thorac Oncol. 2012 Nov; 7(11):1676-82.
    View in: PubMed
    Score: 0.009
  24. Celiac node failure patterns after definitive chemoradiation for esophageal cancer in the modern era. Int J Radiat Oncol Biol Phys. 2012 Jun 01; 83(2):e231-9.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.